IMS Health, which provides healthcare data and consulting services to drug makers, payers and healthcare providers, raised $1.3 billion by offering 65.0 million shares (20% insider) at $20, within the $18-$21 range. At its offer price, IMS Health now commands a $10.5 billion enterprise value and $6.9 billion fully diluted market cap. IMS Health will list on the NYSE under the symbol IMS. J.P. Morgan, Goldman Sachs, Morgan Stanley, BofA Merrill Lynch, Barclays, Deutsche Bank and Wells Fargo Securities all acted as joint bookrunners on the deal.
